ClinicalTrials.gg
CompletedNCT03487562Updated Jun 26, 2019

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects

A Phase 1 interventional study of DWP14012 Amg and DWP14012 Bmg in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-26.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Study summary

This is a randomized, open-label, multiple dose, two-part phase I clinical trial to compare the pharmacokinetics, pharmacodynamics and safety/tolerability of DWP14012 after administrations of DWP14012 alone and combinations of DWP14012, Clarithromycin and Amoxicillin in healthy male subjects

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males aged between 19 and 50 at screening
  • Those whose weight is between 55 and 90 kg and is between 18.0 and 27.0
  • Part I: Those who have been helicobacter pylori negative at screening Part II: Those who have been helicobacter pylori positive at screening
  • Those who are adequate to be subjects in this study upon judgment of the investigator after physical examination, clinical laboratory test, examination by interview, etc

Exclusion criteria

Exclusion Criteria:

  • Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history
  • Those who have gastrointestinal diseases or past history of gastrointestinal diseases (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic evaluation of study drug, and those who have past history of gastrointestinal surgery (however, except simple appendectomy and herniotomy)
  • Those whose plasma (SGOT) and ALT (SGPT) exceed to the
  • Those who have anatomical disability in insertion and maintenance of pH meter catheter
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Part I: A-B-D-C A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid

    Drug: DWP14012 Amg · Drug: Clarithromycin · Drug: Amoxicillin

  • Experimental
    Sequence 2

    Part I: B-C-A-D A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid

    Drug: DWP14012 Amg · Drug: Clarithromycin · Drug: Amoxicillin

  • Experimental
    Sequence 3

    Part I: C-D-B-A A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid

    Drug: DWP14012 Amg · Drug: Clarithromycin · Drug: Amoxicillin

  • Experimental
    Sequence 4

    Part I: D-A-C-B A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid

    Drug: DWP14012 Amg · Drug: Clarithromycin · Drug: Amoxicillin

  • Experimental
    A

    Part II: (DWP14012 B mg + Clarithromycin 500 mg + Amoxicillin 1g) bid

    Drug: DWP14012 Bmg · Drug: Clarithromycin · Drug: Amoxicillin

  • Experimental
    B

    Part II: (DWP14012 A mg + Clarithromycin 500 mg + Amoxicillin 1g) bid

    Drug: DWP14012 Amg · Drug: Clarithromycin · Drug: Amoxicillin

  • Experimental
    C

    Part II: (Lansoprazole 30 mg + Clarithromycin 500 mg + Amoxicillin 1g) bid

    Drug: Clarithromycin · Drug: Amoxicillin · Drug: Lansoprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax,ss: Maximum concentration of DWP14012, clarithromycin and metabolite and amoxicillin at steady state

    Part I: each period (Group A, B, C, D) Part II: Group A, B

    Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours

  2. Cmin,ss: Minimum concentration of DWP14012, clarithromycin and metabolite and amoxicillin at steady state

    Part I: each period (Group A, B, C, D) Part II: Group A, B

    Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours

  3. Cav,ss: Average concentration of DWP14012, clarithromycin and metabolite and amoxicillin at steady state

    Part I: each period (Group A, B, C, D) Part II: Group A, B

    Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours

  4. AUCt,ss: Area under the drug concentration-time curve within a dosing interval at steady states

    Part I: each period (Group A, B, C, D) Part II: Group A, B

    Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours

  5. Tmax,ss: Time of maximum concentration at steady state

    Part I: each period (Group A, B, C, D) Part II: Group A, B

    Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours

  6. T1/2: Elimination half-life

    Part I: each period (Group A, B, C, D) Part II: Group A, B

    Time frame: Day 1~7 pre-dose, Day 8 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48 hours

  7. Percentage of total time that the intragastric pH was above 4

    Part I

    Time frame: Period 1 Day -1 and Group A, C Day 7 0~24 hours

  8. Percentage of total time that the intragastric pH was above 4

    Part II

    Time frame: Day -1, Day 1, Day 7 0~24 hours

  9. Percentage of total time that the intragastric pH was above 6

    Part I

    Time frame: Period 1 day -1 and Group A, C Day 7 0~24 hours

  10. Percentage of total time that the intragastric pH was above 6

    Part II

    Time frame: Day -1, Day 1, Day 7 0~24 hours

  11. Serum gastrin concentration profile

    Part I

    Time frame: Period 1 Day -1 and Group A, C Day 7 pre-dose, 2, 4, 6, 8, 12, 24, 48 hours

  12. Serum gastrin concentration profile

    Part II

    Time frame: Day -1 pre-dose, 2, 4, 6, 8, 12 hours, Day 1 and 7 pre-dose, 2, 4, 6, 8, 12, 24, 48 hours

  13. Number of participants with Adverse Events (AE)

    All AE standardized using MedDRA was assessed by investigator using the protocol defined grading system. Intensity was categorized as mild, moderate and severe

    Time frame: Day -2 (Randomization) to Day 60 (Post-study visit of Part I) and Day 42 (Follow up visit of Part II)

  14. Number of Participants With Clinically Significant Vital Sign findings

    Blood pressure(mmHg), pulse (beats/min) and body temperature(℃) were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.

    Time frame: Day -2 (Randomization) to Day 60 (Post-study visit of Part I) and Day 42 (Follow up visit of Part II)

  15. Number of Participants With Clinically Significant Electrocardiogram(12-lead ECG) findings

    Ventricular rate(beats/min), RR, PR interval(msec), QRS duration(msec), QTcB and QTcF were recorded. The results of 12-lead ECG will be categorized Normal/Abnormal NCS(No clinically significant)/Abnormal CS(clinically significant).

    Time frame: Day -2 (Randomization) to Day 54~60 (Post-study visit of Part I) and Day 36~42 (Follow up visit of Part II)

  16. Number of Participants With Clinically Significant Laboratory results

    Hematology, Blood chemistry, Coagulation and Urinalysis were tested. The Average, Median, Standard Deviation, Min, Max values will be calculated to assess the safety/tolerability.

    Time frame: Day -2 (Randomization) to Day 60 (Post-study visit of Part I) and Day 42 (Follow up visit of Part II)

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jan 2019, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2018
First posted
Apr 4, 2018
StartActual
Apr 8, 2018
Primary completionActual
Jan 11, 2019
CompletionActual
Jan 11, 2019
Last update
Jun 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03487562
Responsible party
Sponsor
First posted
Apr 4, 2018
Start date
Apr 8, 2018
Primary completion
Jan 11, 2019
Completion
Jan 11, 2019
Last update
Jun 26, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion